



This product is part of our PureActives® range.

# Purimox® Powder grade E

## Amoxicillin Trihydrate, powder grade E

### Therapeutical category:

Oral, broad spectrum penicillin

### Characteristics:

A fine crystalline powder. No solvents are used in the process resulting in higher purity of the product.



### Applications:

The product is suitable for the manufacture of tablets, powders and granules for oral suspensions. Grade E ensures high solubility, thermo stability and content uniformity.

### PureActives, the enzymatic difference

All our PureActives® antibiotic products are produced using our proprietary, sustainable, and environmentally friendly enzymatic technology. They bring our brand promise to life through superior quality, outstanding reliability and leading sustainability performance.

All our manufacturing sites use the best available technology and operate dedicated waste water treatment plants, 24/7 throughout the year. Effluents are regularly sampled and checked for antimicrobial activity.

Quality



Reliability



Sustainability



## Key parameters: Purimox<sup>®</sup> Powder grade E

### Amoxicillin Trihydrate, powder grade E

Pharmacopeia quality	USP, EP, IP	
Regulatory information	EU: EDQM Canada: HC in progress Russian Federation: DoH	India: MoH Bangladesh: MoH South Korea: KFDA Taiwan: DoH Australia: TGA
Appearance	White to almost white crystalline powder	
Assay (anhydrous basis)	Amoxicillin: 97.5 - 102.0%	
pH	3.5 - 5.5	
Water	11.5 - 14.5%	
Tapped bulk density	≤ 0.6 g/ml	
Total impurities	≤ 2.0%	
Residual solvents	Not used in the process	
Dimethylaniline	Not used in the process	
Shelf-life	Minimum 5 years in the original packaging under storage conditions	
Batch size	Approximately 300 - 1000 kg	
Storage conditions	Below 25°C, protected from light and moisture	
Packaging	Primary packaging: polyethylene bag	
	Secondary packaging: thermo-sealed aluminum polyethylene bag	
	Outer packaging: corrugated box or HDPE drum	
	Fixed quantity of 25 kg packed in each bag	

#### Contact and information

For more information, please visit [www.centrient.com](http://www.centrient.com) or e-mail: [info@centrient.com](mailto:info@centrient.com) or contact us at one of the addresses below:

Rotterdam (HQ)  
[sales@centrient.com](mailto:sales@centrient.com)

Europe/North America  
Delft, The Netherlands  
[sales.ea@centrient.com](mailto:sales.ea@centrient.com)

Asia Pacific / Middle East / Africa  
Gurgaon, India  
[sales.amea@centrient.com](mailto:sales.amea@centrient.com)

China  
Beijing, P.R. China  
[sales.china@centrient.com](mailto:sales.china@centrient.com)

Mexico & Latin America  
Ramos Arizpe, Mexico  
[sales.mla@centrient.com](mailto:sales.mla@centrient.com)

Copyright © 2019 Centrient Pharmaceuticals. All rights reserved. Although diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein can be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor can it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement.

The content of this document is subject to change without further notice. Please contact us for the latest version of this document or further information. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions like the Bolar provisions in the US and 2004/27/EC in Europe.

VAPFS 2019